Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Cardiovascular Imaging
What is your preferred imaging modality for the evaluation of coronary microvascular dysfunction/INOCA and when would you favor it over coronary angiogram with provocative testing?
Related Questions
What is the best way to categorize aortic stenosis in normal LV function with normal LV size, when the peak velocity and mean pressure gradient are in moderate range but AVA shows severe?
How do you approach a patient at intermediate ASCVD risk who has been referred to you because of an abnormal coronary CTA (obstructive lesion ~90%) but an excellent exercise capacity on treadmill without angina and a negative MPI?
What are your top takeaways from ACC 2024?
What clinical or echocardiographic parameters do you use to determine the optimal timing for an aortic valve intervention in patients with asymptomatic severe aortic stenosis?
What are some high-risk TTE features that would prompt you to consider serial TTEs to look for LV thrombus formation post-MI, and how frequently would you image these patients?
Would you recommend hospitalization for surgery for a large papillary fibroelastoma or atrial myxoma discovered on an outpatient echocardiogram?
For a patient with prior bypass graft stenting and severe native vessel disease, would you recommend myocardial perfusion imaging or coronary CTA if there is concern about graft patency?
How do you distinguish between senile/hypertensive sigmoid septal hypertrophy versus sigmoid septal hypertrophy seen in hypertrophic cardiomyopathy?
Would you favor functional or anatomical assessment for CAD in a patient with intermediate CV risk factors with equivocal or nondiagnostic exercise treadmill testing and normal renal function?
When would you consider using cardiac MRI over nuclear imaging for functional assessment of ischemic heart disease, since it is class IIa indication in the US but otherwise class I in Europe?
